myeloproliferative neoplasms (MPN) | Page 31 | Aplastic Anemia & MDS International Foundation Return to top.

myeloproliferative neoplasms (MPN)

Timothy Graubert, MD

Graubert, Timothy
Director, Hematologic Malignancies Program, Hagler Family Chair in Oncology, Professor of Medicine
Massachusetts General Hospital, Harvard Medical School

Dr. Graubert’s research focuses on the molecular pathogenesis of myeloid leukemias. While at Washington University in St. Louis, he and his colleagues used genome sequencing technology extensively to gain insights into the genetic basis of human cancer and to use this information to improve risk stratification tools and identify targets for novel therapy.  Their group published the first complete genome sequence of a human cancer (

B. Douglas Smith, MD

Smith, B. Douglas
Professor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

B. Douglas Smith is Professor of Oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland, and is on the active staff of Johns Hopkins Hospital. He earned his medical degree at the Medical College of Pennsylvania in Philadelphia, after which he completed an internship, residency, and chief residency at Strong Memorial Hospital in Rochester, New York.  At the completion of his fellowship in Oncology at Johns Hopkins University, he joined the faculty in the Division of Hematologic Malignancies. 

Michael Keng, MD

Keng, Michael
Assistant Professor, Division of Hematology/Oncology
University of Virginia Cancer Center

Dr. Michael Keng holds a clinical faculty appointment in Medicine in the Division of Hematology/Oncology at UVA Cancer Center. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Hospital.

Erica Warlick, MD

Warlick, Erica
Assistant Professor of Medicine
University of Minnesota Medical Center

Dr. Warlick is an Assistant Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. Her clinical and research efforts focus on the treatment of hematologic malignancies. She has particular interest in myeloid malignancies and the development of new strategies utilizing hematopoietic stem cell transplantation, traditional chemotherapeutics, as well as novel biologic modifiers to treat this diverse group of diseases.

Maria Baer, MD

Baer, Maria
Director, Hematologic Malignancies Program
University of Maryland Greenebaum Comprehensive Cancer Center

Maria Baer joined the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, Maryland in 2007 as director of hematologic malignancies and professor of medicine and molecular medicine, University of Maryland School of Medicine. She previously served as chief of the leukemia section at Roswell Park Cancer Institute and professor of medicine and associate professor of molecular pharmacology and cancer therapeutics at the University at Buffalo School of Medicine and Biomedical Sciences in Buffalo, New York.

Share with addtoany.com.